Rest Of Europe Cancer/Tumor Profiling Market (2022-2027)
The Rest Of Europe Cancer/Tumor Profiling Market was valued at $655.9 Million in 2022 and projected to reach to $1141.6 Million by 2027, representing a compound annual growth rate of 11.7%. Rest Of Europe's cancer/tumor profiling market is positioned for substantial growth, expanding from USD 655.9 million in 2022 to USD 1,141.6 million by 2027.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Europe Cancer/Tumor Profiling Market Trends and Insights
- Rest Of Europe is experiencing robust adoption of advanced molecular profiling technologies driven by increasing cancer incidence, rising healthcare investments, and growing demand for personalized oncology solutions.
- The region's market growth is supported by strengthening regulatory frameworks, expanding laboratory infrastructure, and heightened awareness among healthcare providers regarding the clinical benefits of tumor profiling in treatment planning and patient outcomes. Rest Of Europe's cancer/tumor profiling market is characterized by a diverse competitive landscape with both established diagnostic companies and emerging biotech firms expanding their presence.
- The forecast period (2022-2027) reflects accelerating adoption of next-generation sequencing (NGS), immunohistochemistry (IHC), and other profiling methodologies across Rest Of Europe's healthcare systems.
- Key drivers include aging populations, improved reimbursement policies, and integration of profiling services into standard oncology care protocols throughout the region..
Key Market Statistics
- CAGR (2022-2027) 11.7% CAGR
- Market Size, 2022 ~USD 655.9 Million
- Forecast, 2027 ~USD 1141.6 Million
- Country Rest Of Europe
Rest Of Europe Cancer/Tumor Profiling Market Overview
Strong Market Growth :
Rest Of Europe's cancer/tumor profiling market is expanding at 11.7% CAGR, outpacing the global average of 10.6%, driven by increasing cancer prevalence and healthcare modernization across the region.
Rising Molecular Profiling Adoption :
Advanced molecular profiling technologies are gaining traction in Rest Of Europe due to improved reimbursement policies, growing clinical awareness, and integration of genomic testing into standard cancer care protocols.
Increased Healthcare Investment :
European governments and private healthcare systems are significantly investing in oncology infrastructure and precision medicine initiatives, supporting market expansion in Rest Of Europe countries.
Personalized Medicine Demand :
Growing demand for personalized cancer treatment approaches is accelerating adoption of tumor profiling solutions across Rest Of Europe, enabling targeted therapies and improved patient outcomes.
Rest Of Europe Cancer/Tumor Profiling Market Dynamics
- This robust expansion is fueled by increasing cancer incidence rates, enhanced healthcare spending, and widespread adoption of precision oncology practices across the region.
- Healthcare providers are increasingly recognizing the clinical and economic value of molecular profiling in treatment selection and patient stratification. The market outlook remains positive as Rest Of Europe countries continue to strengthen regulatory frameworks for genomic testing, improve laboratory infrastructure, and integrate tumor profiling into national cancer care guidelines.
- Collaborations between academic institutions, diagnostic companies, and healthcare systems are accelerating innovation and market penetration, positioning Rest Of Europe as a key growth driver in the European oncology diagnostics landscape..
Market Ecosystem
CANCER TUMOR PROFILING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Through Foundation Medicine and Roche Diagnostics, the company provides comprehensive genomic profiling (CGP) solutions using tissue and liquid biopsy-based testing to identify actionable biomarkers and support companion diagnostic applications for targeted therapies and immunotherapies. | Enables accurate patient stratification, improves therapy selection, supports biomarker-driven treatment decisions, and accelerates adoption of precision oncology workflows. |
 |
Provides next-generation sequencing (NGS) platforms and oncology-focused assays, including TruSight Oncology Comprehensive, to enable multi-gene tumor profiling and detection of clinically relevant biomarkers across solid tumors. | Supports comprehensive biomarker identification, improves laboratory testing scalability, enables decentralized genomic testing, and supports pharmaceutical companion diagnostic development. |
 |
Provides liquid biopsy-based tumor profiling solutions, including Guardant360 CDx and related genomic testing platforms, for detecting actionable genomic alterations, monitoring treatment response, and supporting therapy selection in advanced cancers. | Enables minimally invasive testing, facilitates repeat monitoring, identifies resistance mechanisms, and expands access to precision oncology testing for patients with limited tissue availability. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Key Takeaways
- Rest Of Europe's cancer/tumor profiling market is projected to grow from USD 655.9 million (2022) to USD 1,141.6 million (2027) at an 11.7% CAGR.
- Rest Of Europe demonstrates higher growth momentum compared to the global average, driven by expanding healthcare infrastructure and personalized medicine adoption.
- Advanced molecular profiling technologies including NGS and IHC are becoming standard practice across Rest Of Europe's oncology centers.
- Rest Of Europe's market benefits from aging demographics, improved reimbursement policies, and integration of profiling into standard cancer care protocols.
Cancer/Tumor Profiling Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2022 |
| Fastest Growing Segment | NEXT-GENERATION SEQUENCING (Technology) |
| Forecast Period | 2022-2027 |
| Growth Rate | CAGR of 10.6% from 2022 to 2027 |
| Largest Segment | RESEARCH APPLICATIONS (Application) |
| Market Size Base Year (Billions) | ~USD 9.67 (2022) |
| Revenue Forecast (Billions) | ~USD 16 (2027) |
| Segments Covered | Technology, Cancer Type, Biomarker Type, Application, Type |
Rest Of Europe Cancer/Tumor Profiling Market Report Segmentation
5 segment dimensions are covered across the global market.
By Technology
- Immunoassays
- In Situ Hybridization
- In-Situ Hybridization
- Mass Spectrometry
- Microarrays
- Next-Generation Sequencing
- Other Technologies
- Others Technologies
- Polymerase Chain Reaction
By Cancer Type
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Melanoma Cancer
- Other Cancers
- Prostate Cancer
By Biomarker Type
- Genetic Biomarkers
- Genomic Biomarkers
- Other Biomarkers
- Protein Biomarkers
By Application
- Clinical Applications
- Research Applications
By Type
- Biomarker Discovery
- Diagnostics
- Monitoring & Treatment
- Personalized Medicine
- Prognostics
- Screening
Target Audience
- Diagnostic Companies & IVD Manufacturers : Need Rest Of Europe-specific market data to develop regional commercialization strategies, identify market gaps, and optimize product portfolios for European precision oncology adoption.
- Healthcare Providers & Hospital Networks : Require market insights to evaluate tumor profiling technology investments, benchmark against regional peers, and align oncology service offerings with emerging precision medicine standards in Rest Of Europe.
- Pharmaceutical & Biotech Companies : Need Rest Of Europe market intelligence to support companion diagnostic development, identify patient populations for targeted therapies, and plan regional clinical trial strategies.
- Healthcare Investors & Private Equity : Seek detailed Rest Of Europe market analysis to evaluate investment opportunities in diagnostic platforms, oncology services, and precision medicine companies with regional growth potential.
- Healthcare Policy & Government Agencies : Require market data to inform cancer care policy development, healthcare budget allocation, and precision medicine infrastructure planning across Rest Of Europe countries.
Reasons to Buy this Report
- Regional Market Sizing & Forecasts : Obtain precise market valuations specific to Rest Of Europe (USD 655.9M in 2022, USD 1,141.6M in 2027) with detailed CAGR analysis to support strategic planning and investment decisions in the region.
- Competitive Landscape Intelligence : Understand key players, market share distribution, and competitive strategies specific to Rest Of Europe's cancer profiling sector to identify partnership and acquisition opportunities.
- Growth Driver Analysis : Identify region-specific growth catalysts including healthcare policies, reimbursement trends, and clinical adoption patterns unique to Rest Of Europe countries for targeted market entry strategies.
- Technology & Solution Trends : Analyze emerging molecular profiling technologies, diagnostic platforms, and service models gaining traction in Rest Of Europe to align product development and commercialization efforts.
- Regulatory & Reimbursement Insights : Access detailed information on Rest Of Europe regulatory frameworks, reimbursement policies, and healthcare system dynamics essential for market access and pricing strategy development.
Frequently asked questions
What is the market size of cancer/tumor profiling in Rest Of Europe?
Rest Of Europe's cancer/tumor profiling market was valued at USD 655.9 million in 2022 and is expected to reach USD 1,141.6 million by 2027.
What is the CAGR for Rest Of Europe's cancer/tumor profiling market?
Rest Of Europe's cancer/tumor profiling market is projected to grow at a CAGR of 11.7% from 2022 to 2027.
What are the primary growth drivers in Rest Of Europe?
Key growth drivers in Rest Of Europe include increasing cancer prevalence, rising healthcare investments, expanding laboratory infrastructure, improved reimbursement policies, and growing adoption of personalized oncology approaches.
Which profiling technologies are most prevalent in Rest Of Europe?
Rest Of Europe is experiencing widespread adoption of next-generation sequencing (NGS), immunohistochemistry (IHC), and other advanced molecular profiling methodologies in oncology care.
How does Rest Of Europe's market growth compare to global trends?
Rest Of Europe's 11.7% CAGR exceeds the global average of 10.6%, reflecting stronger regional demand for cancer profiling services and favorable healthcare policies.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the cancer tumor profiling market. Exhaustive secondary research was conducted to collect information on the market, its peer markets, and the broader precision-oncology ecosystem. The findings, assumptions, and market sizing estimates were then validated through primary research with participants across the value chain. Both top-down and bottom-up approaches were used to estimate the complete market. Following this, data triangulation was applied to finalize the market size and the values of individual segments and subsegments.
Secondary Research
Secondary research was used to identify and gather information for this extensive technical, market-oriented, and commercial study. Public-sector sources included the US Food and Drug Administration (FDA), National Institutes of Health (NIH), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), International Agency for Research on Cancer (IARC), Global Cancer Observatory (GLOBOCAN), European Medicines Agency (EMA), European Commission, and relevant national health ministries and cancer registries.
Company and industry sources included annual reports, SEC and other regulatory filings, investor presentations, earnings releases, product catalogs, regulatory databases, company websites, scientific publications, clinical trial registries, peer-reviewed journals, and publications from pathology, genomics, oncology, and laboratory medicine associations. These sources were used to identify major participants, product and service portfolios, regulatory approvals, installed sequencing and pathology capabilities, test volumes, oncology revenue exposure, partnerships, clinical-trial activity, regional presence, technology adoption, and market developments.
Secondary data were analyzed to estimate the overall cancer tumor profiling market and to construct preliminary splits by product and service, technology, sample type, application, cancer type, end user, and region. The resulting estimates were subsequently validated and refined through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including executives of diagnostics and life-science companies, laboratory directors, molecular pathologists, oncologists, sequencing specialists, product managers, business-development leaders, clinical-trial professionals, and subject-matter experts. Interviews were conducted across both the supply and demand sides to validate market definitions, adoption levels, average selling prices, test volumes, technology mix, regional variation, end-user behavior, growth assumptions, and competitive positioning:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global cancer tumor profiling market was estimated through multiple complementary approaches. A detailed market-engineering model was used to estimate and validate the overall market and each segment. The process combined company-level revenue analysis, product and service mapping, test-volume assessment, installed-base evaluation, average selling price analysis, end-user demand estimation, and regional adoption patterns. The research methodology used to estimate the market size includes the following:
Cancer Tumor Profiling Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market through the market-size estimation process, the total market was split into the defined segments and subsegments. To complete the market-engineering process and arrive at the final statistics, data triangulation was employed. The process examined factors and trends from both the demand and supply sides and reconciled company revenues, test volumes, installed systems, consumable pull-through, service revenue, technology adoption, cancer incidence, biomarker-testing patterns, and regional market conditions.
The final estimates were checked for consistency across all dimensions. For example, the product and service totals were reconciled with technology, sample type, application, cancer type, end user, and regional totals. Company-share estimates were also compared with the independently derived global market size to ensure that no major revenue pools were omitted or double-counted.
Market Definition
Cancer tumor profiling refers to the analysis of molecular, genomic, proteomic, and histopathologic characteristics of tumor material to support cancer diagnosis and molecular characterization, prognostic or risk assessment, treatment selection, companion diagnostic use, treatment-response and resistance monitoring, residual disease assessment, post-treatment surveillance, recurrence detection, biomarker discovery, and oncology drug development.
The market includes instruments and systems; assays, kits, reagents, and consumables; clinical tumor profiling testing services; and biopharmaceutical, clinical-trial, and companion diagnostic services. It covers next-generation sequencing, PCR-based technologies, immunohistochemistry, in situ hybridization, and other tumor profiling technologies applied to tissue, whole blood and plasma, bone marrow, and other relevant samples across solid tumors and hematologic malignancies.
The market excludes unrelated general laboratory testing, non-oncology molecular diagnostics, routine pathology procedures that do not contribute to tumor characterization, and hereditary or germline testing performed outside a cancer tumor profiling workflow.
Key Stakeholders
- Manufacturers and distributors of cancer tumor profiling instruments and systems
- Assay, kit, reagent, antibody, probe, and consumable suppliers
- Next-generation sequencing, PCR, IHC, and ISH technology providers
- Clinical tumor profiling and liquid-biopsy testing laboratories
- Hospitals, dedicated cancer centers, and oncology clinics
- Independent and specialty reference laboratories
- Pharmaceutical and biotechnology companies
- Contract research organizations and central laboratories
- Companion diagnostic developers and service providers
- Research institutes and academic medical center laboratories
- Regulatory agencies, reimbursement bodies, and cancer registries
- Market research and consulting firms
- Private equity firms, venture capitalists, and other investors.
Report Objectives
- To define, describe, segment, and forecast the global cancer tumor profiling market by offering, technology, sample type, application, cancer type, end user, and region
- To provide detailed information regarding the major factors influencing market growth, including drivers, restraints, opportunities, and challenges
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall cancer tumor profiling market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to six regions: North America(US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC and the Rest of Middle East], and Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, collaborations, expansions, and other developments
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
-
Further breakdown of the Rest of Europe cancer/tumor profiling market, by country
-
Further breakdown of the Rest of Asia Pacific cancer/tumor profiling market, by country
Company Information
-
Detailed analysis and profiling of additional market players (up to five)
-
Further breakup of additional Asia Pacific countries by offering, deployment mode, enterprise size, application, and vertical
-
Further breakup of additional Middle Eastern & African countries by offering, deployment mode, enterprise size, application, and vertical
Segment Analysis
- Cross-segment analysis
Get the Full Cancer/Tumor Profiling Market Report
Full forecast, segment splits, and company analysis for all Cancer/Tumor Profiling Market.
- Canada Cancer/Tumor Profiling Market
- US Cancer/Tumor Profiling Market
- France Cancer/Tumor Profiling Market
- Germany Cancer/Tumor Profiling Market
- Italy Cancer/Tumor Profiling Market
- Spain Cancer/Tumor Profiling Market
- UK Cancer/Tumor Profiling Market
- China Cancer/Tumor Profiling Market
- India Cancer/Tumor Profiling Market
- Japan Cancer/Tumor Profiling Market
- Roapac Cancer/Tumor Profiling Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
